Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date

References

• WenzelSEEmergence of biomolecular pathways to define novel asthma phenotypes. Type-2 immunity and beyondAm J Respir Cell Mol Biol20165511427164162
   PubMed Web of Science ®Google Scholar
• ParulekarADDiamantZHananiaNARole of T2 inflammation bio-markers in severe asthmaCurr Opin Pulm Med2016221596826574724
   PubMed Web of Science ®Google Scholar
• ParulekarADKaoCCDiamantZHananiaNATargeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needsCurr Opin Pulm Med2018241505529036019
   PubMed Web of Science ®Google Scholar
• TakatsuKNakajimaHIL-5 and eosinophiliaCurr Opin Immunol200820328829418511250
   PubMed Web of Science ®Google Scholar
• MooreWCMeyersDAWenzelSENational Heart, Lung, and Blood Institute’s Severe Asthma Research ProgramIdentification of asthma phenotypes using cluster analysis in the severe asthma research programAm J Respir Crit Care Med2010181431532319892860
   PubMed Web of Science ®Google Scholar
• SirouxVBasagañaXBoudierAIdentifying adult asthma phenotypes using a clustering approachEur Respir J201138231031721233270
   PubMed Web of Science ®Google Scholar
• GauthierMRayAWenzelSEEvolving concepts of asthmaAm J Respir Crit Care Med2015192666066826161792
   PubMed Web of Science ®Google Scholar
• LevineSJWenzelSENarrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypesAnn Intern Med2010152423223720157138
   PubMed Web of Science ®Google Scholar
• KostenisEUlvenTEmerging roles of DP and CRTH2 in allergic inflammationTrends Mol Med200612414815816545607
   PubMed Web of Science ®Google Scholar
• NagataKHiraiHTanakaKCRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s)FEBS Lett1999459219519910518017
   PubMed Web of Science ®Google Scholar
• XueLSalimiMPanseIProstaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cellsJ Allergy Clin Immunol201413341184119424388011
   PubMed Web of Science ®Google Scholar
• HiraiHTanakaKYoshieOProstaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2J Exp Med2001193225526211208866
   PubMed Web of Science ®Google Scholar
• HataANBreyerRMPharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulationPharmacol Ther2004103214716615369681
   PubMed Web of Science ®Google Scholar
• KabashimaKNarumiyaSThe DP receptor, allergic inflammation and asthmaProstaglandins Leukot Essent Fatty Acids2003692–318719412895602
   PubMed Web of Science ®Google Scholar
• GervaisFGCruzRPChateauneufASelective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DPJ Allergy Clin Immunol2001108698298811742277
   PubMed Web of Science ®Google Scholar
• JohnstonSLBardinPGHarrisonJRitterWJoubertJRHolgateSTThe effects of an oral thromboxane TP receptor antagonist BAY u 3405, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrationsBr J Clin Pharmacol19923454024081467134
   PubMed Web of Science ®Google Scholar
• WojnoEDMonticelliLATranSVThe prostaglandin D2 receptor CRTH2 regulates accumulation of group 2 innate lymphoid cells in the inflamed lungMucosal Immunol2015861313132325850654
   PubMed Web of Science ®Google Scholar
• CreaAENakhosteenJALeeTHMediator concentrations in bronchoalveolar lavage fluid of patients with mild asymptomatic bronchial asthmaEur Respir J1992521901951348480
   PubMed Web of Science ®Google Scholar
• LiuMCBleeckerERLichtensteinLMEvidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthmaAm Rev Respir Dis199014211261322368958
   PubMed Web of Science ®Google Scholar
• WenzelSEWestcottJYSmithHRLarsenGLSpectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediatorsAm Rev Respir Dis198913924504572643903
   PubMed Web of Science ®Google Scholar
• MutalithasKGuillenCDayCBrightlingCEPavordIDWardlawAJCRTH2 expression on T cells in AsthmaClin Exp Immunol20101611344020491797
   PubMed Web of Science ®Google Scholar
• BalzarSFajtMLComhairSAMast cell phenotype, location, and activation in severe asthma. Data from the severe asthma research programAm J Respir Crit Care Med2011183329930920813890
   PubMed Web of Science ®Google Scholar
• FajtMLGelhausSLFreemanBProstaglandin D2 pathway upregulation: relation to asthma severity, control, and TH2 inflammationJ Allergy Clin Immunol201313161504151223506843
   PubMed Web of Science ®Google Scholar
• MurrayJJTonnelABBrashARRelease of prostaglandin D2 into human airways during acute antigen challengeN Engl J Med1986315138008043462506
   PubMed Web of Science ®Google Scholar
• PearsonDWeissHMJinYAbsorption, distribution, metabolism, and excretion of the oral prostaglandin D2 receptor 2 antagonist fevipiprant (QAW039) in healthy volunteers and in vitroDrug Metab Dispos201745781782528442499
   PubMed Web of Science ®Google Scholar
• ErpenbeckVJVetsEGheyleLPharmacokinetics, safety, and tolerability of fevipiprant (QAW039), a novel CRTh2 receptor antagonist: results from 2 randomized, phase 1, placebo-controlled studies in healthy volunteersClin Pharmacol Drug Dev20165430631327310331
   PubMed Web of Science ®Google Scholar
• ErpenbeckVJPopovTAMillerDThe oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthmaPulm Pharmacol Ther201639546327354118
   PubMed Web of Science ®Google Scholar
• GonemSBerairRSingapuriAFevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trialLancet Respir Med20164969970727503237
   PubMed Web of Science ®Google Scholar
• BatemanEDGuerrerosAGBrockhausFFevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroidsEur Respir J2017502170067028838980
   PubMed Web of Science ®Google Scholar
• BrusselleGGProvoostSMaesTProstaglandin D2 receptor antagonism: a novel therapeutic option for eosinophilic asthma?Lancet Respir Med20164967667727503236
   PubMed Web of Science ®Google Scholar
• KunaPBjermerLTornlingGTwo Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthmaDrug Des Devel Ther20161027592770
   PubMed Web of Science ®Google Scholar
• BarnesNPavordIChuchalinAA randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthmaClin Exp Allergy2012421384821762224
   PubMed Web of Science ®Google Scholar
• PettipherRHunterMGPerkinsCMHeightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459Allergy20146991223123224866478
   PubMed Web of Science ®Google Scholar
• DiamantZSidhartaPNSinghDSetipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmaticsClin Exp Allergy20144481044105224964348
   PubMed Web of Science ®Google Scholar
• HallIPFowlerAVGuptaAEfficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatmentPulm Pharmacol Ther201532374425861737
   PubMed Web of Science ®Google Scholar
• BusseWWWenzelSEMeltzerEOSafety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patientsJ Allergy Clin Immunol2013131233934523174659
   PubMed Web of Science ®Google Scholar